Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2021-11, Vol.138 (19), p.1901-1905
Hauptverfasser:	Jiménez-Ubieto, Ana, Paiva, Bruno, Puig, Noemi, Cedena, Maria-Teresa, Martínez-López, Joaquín, Oriol, Albert, Blanchard, María-Jesús, Ríos, Rafael, Martin, Jesús, Martínez, Rafael, Sureda, Anna, Hernández, Miguel-Teodoro, de la Rubia, Javier, Krnisk, Isabel, Cabañas, Valentín, Palomera, Luis, Sánchez-Pina, José María, Bargay, Joan, Mateos, María-Victoria, Rosiñol, Laura, Blade, Joan, San Miguel, Jesús, Lahuerta, Juan José
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bortezomib - therapeutic use Clinical Trials and Observations Dexamethasone - therapeutic use Humans Induction Chemotherapy Lenalidomide - therapeutic use Letter to Blood Lymphoid Neoplasia Multiple Myeloma - diagnosis Multiple Myeloma - therapy Prognosis Progression-Free Survival Stem Cell Transplantation Transplantation Transplantation, Autologous Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!